Advice
In the absence of a submission from the holder of the marketing authorisation:
osilodrostat (Isturisa®) is not recommended for use within NHSScotland.
Indication under review: treatment of endogenous Cushing’s syndrome in adults.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice233KB (PDF)
Medicine details
- Medicine name:
- osilodrostat (Isturisa)
- SMC ID:
- SMC2640
- Indication:
For treatment of endogenous Cushing’s syndrome in adults.
- Pharmaceutical company
- Recordati Pharmaceuticals
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 December 2023